Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 4:06 AM
Ignite Modification Date: 2025-12-25 @ 4:06 AM
NCT ID: NCT03890120
Eligibility Criteria: Key Inclusion Criteria: * Diagnosis of large duct PSC * Liver biopsy at screening that is deemed acceptable for interpretation and demonstrates stage F0 - F3 fibrosis in the opinion of the central reader * Individual has the following laboratory parameters at the screening visit, as determined by the central laboratory: * Platelet count ≥ 150,000/mm\^3 * Estimated glomerular filtration rate (eGFR) ≥ 30 milliliter/minute (mL/min), as calculated by the Cockcroft-Gault equation * Alanine transaminase (ALT) ≤ 8 x upper limit of the normal range (ULN) * Total bilirubin \< 2 mg/dL, unless the individual is known to have Gilbert's syndrome or hemolytic anemia * International normalized ratio (INR) ≤ 1.4, unless due to therapeutic anticoagulation * Negative anti-mitochondrial antibody Key Exclusion Criteria: * Current or prior history of any of the following: * Cirrhosis * Liver transplantation * Cholangiocarcinoma or hepatocellular carcinoma (HCC) * Ascending cholangitis within 30 days of screening * Presence of a percutaneous drain or biliary stent * Other causes of liver disease * Current or prior history of unstable cardiovascular disease * Current moderate to severe inflammatory bowel disease (IBD) (including ulcerative colitis, Crohn's disease, and indeterminate colitis) Note: Other protocol defined Inclusion/Exclusion criteria may apply
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 75 Years
Study: NCT03890120
Study Brief:
Protocol Section: NCT03890120